JANX News

10 IPOs and nine SPACs went public this past week as the IPO market continues to heat up heading into summer. The IPO pipeline stayed active as well, with 12 IPOs and seven SPACs submitting initial filings. Payment card platform Marqeta (MQ) priced above the range to raise $1.2 billion at a $15.4 billion market cap. Marqeta provides an open API platform for...read more

Janux Therapeutics, a preclinical biotech developing novel T cell engagers for solid tumors, raised $194 million by offering 11.4 million shares at $17, the high end of the range of $15 to $17. The company offered 1.9 million more shares than anticipated. At pricing, Janux Therapeutics commands a fully diluted market value of $728 million. Janux is developing next-generation...read more

Janux Therapeutics, a preclinical biotech developing a novel class of T cell engagers for cancer, announced terms for its IPO on Monday. The La Jolla, CA-based company plans to raise $152 million by offering 9.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Janux Therapeutics would command a fully diluted market value of $652 million. ...read more

Updated Monday, 6/7. Nine IPOs are currently slated to raise $3.9 billion, featuring digital payments, mental health services, and more. Payments platform Marqeta (MQ) plans to raise $1.0 billion at a $12.4 billion market cap. The company's platform allows businesses to launch and manage their own card programs, issue cards to their customers or...read more